CA2775309C - A phenol derivative and its pharmaceutical use - Google Patents

A phenol derivative and its pharmaceutical use Download PDF

Info

Publication number
CA2775309C
CA2775309C CA2775309A CA2775309A CA2775309C CA 2775309 C CA2775309 C CA 2775309C CA 2775309 A CA2775309 A CA 2775309A CA 2775309 A CA2775309 A CA 2775309A CA 2775309 C CA2775309 C CA 2775309C
Authority
CA
Canada
Prior art keywords
added
mixture
group
dihydro
benzothiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2775309A
Other languages
English (en)
French (fr)
Other versions
CA2775309A1 (en
Inventor
Seiichi Kobashi
Junichiro Uda
Sachiho Miyata
Tsutomu Inoue
Naoki Ashizawa
Koji Matsumoto
Tetsuya Taniguchi
Takashi Iwanaga
Osamu Nagata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Yakuhin Co Ltd
Original Assignee
Fuji Yakuhin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43826265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2775309(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fuji Yakuhin Co Ltd filed Critical Fuji Yakuhin Co Ltd
Publication of CA2775309A1 publication Critical patent/CA2775309A1/en
Application granted granted Critical
Publication of CA2775309C publication Critical patent/CA2775309C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA2775309A 2009-09-30 2010-09-29 A phenol derivative and its pharmaceutical use Active CA2775309C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009-227402 2009-09-30
JP2009227402A JP5325065B2 (ja) 2009-09-30 2009-09-30 新規フェノール誘導体
PCT/JP2010/066925 WO2011040449A1 (ja) 2009-09-30 2010-09-29 新規フェノール誘導体

Publications (2)

Publication Number Publication Date
CA2775309A1 CA2775309A1 (en) 2011-04-07
CA2775309C true CA2775309C (en) 2017-12-12

Family

ID=43826265

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2775309A Active CA2775309C (en) 2009-09-30 2010-09-29 A phenol derivative and its pharmaceutical use

Country Status (23)

Country Link
US (1) US8367843B2 (enExample)
EP (1) EP2484669B1 (enExample)
JP (1) JP5325065B2 (enExample)
KR (1) KR101647174B1 (enExample)
CN (1) CN102639518B (enExample)
AU (1) AU2010301675B2 (enExample)
BR (1) BR112012007069B1 (enExample)
CA (1) CA2775309C (enExample)
DK (1) DK2484669T3 (enExample)
ES (1) ES2549603T3 (enExample)
HU (1) HUE026007T2 (enExample)
IL (1) IL218519A (enExample)
IN (1) IN2012DN02551A (enExample)
MX (1) MX2012003392A (enExample)
MY (1) MY160394A (enExample)
NZ (1) NZ598582A (enExample)
PH (1) PH12012500643A1 (enExample)
PL (1) PL2484669T3 (enExample)
PT (1) PT2484669E (enExample)
RU (1) RU2536689C2 (enExample)
TW (1) TWI461195B (enExample)
WO (1) WO2011040449A1 (enExample)
ZA (1) ZA201201895B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5851802B2 (ja) 2011-03-30 2016-02-03 富士重工業株式会社 炭素繊維強化樹脂複合材用ドリル
WO2015191034A1 (en) * 2014-06-09 2015-12-17 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
WO2017038799A1 (ja) * 2015-09-04 2017-03-09 サントリーホールディングス株式会社 ウレアーゼ活性阻害剤
ES2803223T3 (es) * 2015-09-10 2021-01-25 Jiangsu Atom Bioscience And Pharmaceutical Co Ltd Imidazo[1,2A]piridinas para tratar o prevenir la hiperuricemia o la gota
CN105675557B (zh) * 2016-01-07 2019-01-25 济南大学 基于苯炔荧光试剂检测硫脲含量的新方法
AU2017298142B2 (en) 2016-07-18 2021-11-11 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
WO2018199277A1 (ja) * 2017-04-28 2018-11-01 株式会社富士薬品 ３－（３，５－ジクロロ－４－ヒドロキシベンゾイル）－１，１－ジオキソ－２，３－ジヒドロ－１，３－ベンゾチアゾールの結晶形及び塩
CN109928890B (zh) * 2017-12-15 2021-11-09 重庆常捷医药有限公司 一种托伐普坦中间体2-甲基-4-n-(2-甲基苯甲酰)苯甲酸的制备方法
KR20210102933A (ko) 2018-12-06 2021-08-20 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방 방법
BR112021010708A2 (pt) 2018-12-06 2021-08-24 Arthrosi Therapeutics, Inc. Formas cristalinas de um composto para tratar ou prevenir gota ou hiperuricemia
CA3159300A1 (en) * 2019-12-09 2021-06-17 Tadashi Inoue Solid pharmaceutical preparation
CN111675675A (zh) * 2020-07-17 2020-09-18 苏州明锐医药科技有限公司 多替诺德的制备方法
CN111662247A (zh) * 2020-07-17 2020-09-15 苏州明锐医药科技有限公司 一种多替诺德的合成方法
CN112430221B (zh) * 2020-11-20 2023-06-23 成都诺和晟泰生物科技有限公司 用于预防、治疗或减轻高尿酸血症或痛风的化合物及其应用
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
CN114903879B (zh) * 2022-06-23 2023-10-31 东北大学 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途
CN115160314B (zh) * 2022-07-28 2023-12-05 南方医科大学 杂环芳酰胺类化合物及其制备方法和应用
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use
CN118580197A (zh) * 2023-11-16 2024-09-03 广东东阳光药业股份有限公司 一种多替诺雷制备方法及其应用
CN119241468A (zh) * 2024-09-27 2025-01-03 杭州善礼生物医药科技有限公司 一种多替诺雷中间体的合成方法
CN119930540A (zh) * 2025-01-21 2025-05-06 杭州善礼生物医药科技有限公司 一种多替诺雷的制备方法
CN121226282A (zh) * 2025-05-22 2025-12-30 武汉武药科技有限公司 一种化合物原料药及其药物组合物和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720683A (en) * 1970-09-02 1973-03-13 Squibb & Sons Inc 2-phenyl-3-acylbenzothiazolines and their oxides
WO2005121112A1 (ja) 2004-06-10 2005-12-22 Torii Pharmaceutical Co., Ltd. ６－ヒドロキシベンズブロマロン又はその塩からなる医薬組成物
JP3988832B2 (ja) 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
EP1985297A1 (en) * 2006-01-27 2008-10-29 Japan Tobacco, Inc. Carboxylic acid compound and use thereof
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
WO2008062740A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Composé azoté à anneaux fusionnés et son utilisation

Also Published As

Publication number Publication date
MY160394A (en) 2017-03-15
KR20120080183A (ko) 2012-07-16
PL2484669T3 (pl) 2015-12-31
BR112012007069B1 (pt) 2020-03-03
HUE026007T2 (en) 2016-05-30
CN102639518A (zh) 2012-08-15
EP2484669A1 (en) 2012-08-08
IL218519A (en) 2016-03-31
DK2484669T3 (en) 2015-09-21
JP5325065B2 (ja) 2013-10-23
CN102639518B (zh) 2015-03-25
CA2775309A1 (en) 2011-04-07
EP2484669A4 (en) 2013-02-27
WO2011040449A1 (ja) 2011-04-07
TW201121544A (en) 2011-07-01
AU2010301675A1 (en) 2012-04-05
US20120184587A1 (en) 2012-07-19
KR101647174B1 (ko) 2016-08-09
AU2010301675B2 (en) 2013-08-22
RU2536689C2 (ru) 2014-12-27
US8367843B2 (en) 2013-02-05
IL218519A0 (en) 2012-07-31
RU2012117786A (ru) 2013-11-10
TWI461195B (zh) 2014-11-21
ZA201201895B (en) 2013-09-25
IN2012DN02551A (enExample) 2015-08-28
MX2012003392A (es) 2012-04-10
NZ598582A (en) 2013-04-26
PH12012500643A1 (en) 2012-11-12
HK1169650A1 (en) 2013-02-01
JP2011074017A (ja) 2011-04-14
EP2484669B1 (en) 2015-07-29
ES2549603T3 (es) 2015-10-29
PT2484669E (pt) 2015-10-30
BR112012007069A2 (pt) 2016-04-19

Similar Documents

Publication Publication Date Title
CA2775309C (en) A phenol derivative and its pharmaceutical use
JP6569792B2 (ja) ハロゲン置換へテロ環化合物
KR101507173B1 (ko) 페록시좀 증식제 활성화 수용체 δ 의 활성화제
TWI666201B (zh) 稠環衍生物、其製備方法、中間體、藥物組合物及應用
WO2004106276A1 (ja) 縮合環化合物
TW200400027A (en) Compounds that modulate PPAR activity
EP1419770A1 (en) Apo ai expression accelerating agent
WO2018005807A1 (en) 1 h-pyrazol-1 -yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof
WO1990005132A1 (fr) Derives d'allylamine substitues, procede de preparation et utilisation
CN118103357A (zh) Fabp4/5抑制剂、使用方法和制备方法
US20220289698A1 (en) Inhibitors of human atgl
HK1169650B (en) Novel phenol derivative
JPH0499770A (ja) ロダニン誘導体
HK1226055B (zh) 稠环衍生物、其制备方法、中间体、药物组合物及应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150417

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250626